Reuters reports Experimental Novartis drug slows kidney cancer.
"An experimental drug from Swiss drugmaker Novartis slowed the progression of kidney cancer in patients whose tumors returned after initial chemotherapy, researchers reported on Friday.
"The drug, called RAD-001 or everolimus, may provide an option for patients with a difficult-to-treat cancer, the researchers said in an initial release of data ahead of a meeting of the American Society of Clinical Oncology.
Kidney cancer will be diagnosed in 54,390 people in the United States this year and will kill 13,010, the American Cancer Society projects, so this kind of drug can make a massive difference. Let's hope this early success is continued and the drug makes it onto the market!